Healthcare
MediciNova, Inc.(MNOV)
Live Price
Offline$1.30
-1.52% today
1Y Change
+0.00%
Window
Jun 26, 2025 โ Jun 22, 2026
- Market Cap
- $70.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -4.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 26, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MediciNova, Inc. (MNOV) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.30 and up 0.0% across the available one-year price window (Jun 26, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -4.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -4.3%, free cash flow +7.8% with operating margin -3242.5% and ROIC -31.6%. Valuation already assumes a fairly strong business story at price/sales 168.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MNOV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-3242.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -4.3%, with operating margin around -3242.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -0.7% | +0.0% | -8.0% |
2026 Feb 20, 2026 | +47.4% | -0.7% | -3.3% | +4.0% |
2025 Nov 12, 2025 | +25.0% | -1.9% | -8.9% | -3.8% |
Benchmark Edge
MNOV vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MNOV
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MNOV Max Drawdown
-34.57%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MNOV and SPY.
Company Overview
MediciNova, Inc.
NASDAQ Global Market
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
- Leadership
- Yuichi Iwaki
- IPO Date
- Dec 8, 2006
- Employees
- 13
- Street Address
- 4275 Executive Square
- Mailing
- La Jolla, CA, 92037
- Region
- La Jolla, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 373 1500
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 168.2
- Price/Book
- 1.7
Growth
- Revenue
- 0.0%
- EPS
- -4.3%
- Free Cash Flow
- +7.8%
Profitability
- Gross Margin
- 7.6%
- Operating Margin
- -3242.5%
- Net Margin
- -2928.8%
- ROE
- -26.3%
- ROIC
- -31.6%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 8.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.